<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>GIDS Research Radar · South Georgia and the South Sandwich Islands</title>
  <link>https://globalinfectiousdisease.com/research/</link>
  <description>Published infectious-disease literature filtered to South Georgia and the South Sandwich Islands.</description>
  <language>en</language>
  <atom:link href="https://globalinfectiousdisease.com/research/rss/countries/gs.xml" rel="self" type="application/rss+xml" />
  <lastBuildDate>Sat, 07 Nov 2026 03:45:11 GMT</lastBuildDate>
  <item>
    <title>Crimean-congo hemorrhagic fever in Iraq, 2021–2024: epidemiological and clinical data analysis with proposed severity indicators for resource-constrained settings</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1186-s12879-026-12759-z-c93f0fc4/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1186-s12879-026-12759-z-c93f0fc4/</guid>
    <pubDate>Mon, 02 Feb 2026 00:00:00 GMT</pubDate>
    <description>Easy bedside indicators such as epistaxis and jaundice may support earlier triage and risk stratification for severe CCHF in resource-constrained Iraqi settings.</description>
    <category>Hemorrhagic Fever</category>
    <category>Crimean-Congo hemorrhagic fever</category>
    <category>Surveillance</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1016-s2666-5247-24-00024-7-d49694a1/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1016-s2666-5247-24-00024-7-d49694a1/</guid>
    <pubDate>Mon, 01 Jul 2024 00:00:00 GMT</pubDate>
    <description>The candidate MVA-based T-cell vaccine did not reduce viral shedding in a controlled H3N2 model, suggesting limited immediate public-health benefit for that endpoint.</description>
    <category>Influenza</category>
    <category>Treatment</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Randomised controlled trial</category>
  </item>
</channel>
</rss>
